Seikagaku
4548.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥23.6bn | ¥26.6bn | ¥25.1bn | ¥22.1bn | ¥25.2bn | ¥21.0bn |
| Operating income | −¥1.9bn | ¥440m | −¥332m | ¥0 | ¥2.3bn | ¥1.3bn |
| Ordinary income | ¥589m | ¥1.3bn | ¥1.8bn | ¥1.8bn | ¥3.7bn | ¥2.0bn |
| Total assets | ¥67.4bn | ¥66.5bn | ¥66.7bn | ¥63.1bn | ¥64.6bn | ¥62.4bn |
| Net assets / equity | ¥60.1bn | ¥59.3bn | ¥60.3bn | ¥56.7bn | ¥58.0bn | ¥57.8bn |
| EPS (basic) | ¥13.5 | ¥16.9 | ¥46.5 | ¥32.55 | ¥44.34 | ¥61.86 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 203 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| LAL | ¥12.2bn | ¥975m |
| Pharmaceutical | ¥24.5bn | −¥1.6bn |
| Total | ¥36.6bn | −¥660m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.